

## Special Issue

# Recent Advances in Malaria Vaccine Development—2nd Edition

### Message from the Guest Editors

Infections caused by malaria parasites constitute a major burden on human health in affected regions globally. As one of the deadliest parasitic diseases, malaria continues to cause significant morbidity and mortality, with an estimated 263 million clinical cases and 597,000 deaths reported in 2023\*. Increasing resistance to anti-malarial drugs continues to be a major concern in the fight against the disease.

While *Plasmodium falciparum* causes the majority of malaria-related mortality, safe and efficacious vaccines for both *P. falciparum* and *P. vivax* are needed as cost-effective tools for the prevention and elimination of malaria globally. Importantly, in addition to the only two recently recommended vaccines for the prevention of falciparum malaria in children living in endemic areas (RTS, S/AS01B and R21/Matrix-M), multiple vaccines are required against malaria to provide high efficacy and meet the malaria vaccine supply capacity. This Special Issue of *Vaccines* aims to showcase new developments in both falciparum and vivax malaria vaccines. We look forward to your contributions.

---

### Guest Editors

Dr. Ahmad Rushdi Shakri

Division of Infectious Disease and International Medicine, Department of Internal Medicine, University of South Florida, 3720 Spectrum Blvd, Tampa, FL 33612, USA

Dr. Dipak Raj

Division of Infectious Disease and International Medicine, Department of Internal Medicine, University of South Florida, 3720 Spectrum Blvd, Tampa, FL 33612, USA

---

### Deadline for manuscript submissions

31 December 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/250755](https://mdpi.com/si/250755)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).